LEVETIRACETAM TEVA ® 250 MG

Pays: Israël

Langue: anglais

Source: Ministry of Health

Ingrédients actifs:

LEVETIRACETAM 250 MG

Disponible depuis:

TEVA PHARMACEUTICAL INDUST.LTD

Code ATC:

N03AX14

forme pharmaceutique:

TABLETS

Mode d'administration:

PER OS

Fabriqué par:

TEVA PHARMACEUTICAL INDUSTRIES LTD

Groupe thérapeutique:

LEVETIRACETAM

indications thérapeutiques:

- Levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - Levetiracetam is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.- Levetiracetam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patient from 16 years of age with newly diagnosed epilepsy.- Levetiracetam is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Date de l'autorisation:

2009-09-01